Roche Molecular Systems, Inc.
4300 Hacienda Drive
Pleasanton
California
94588
U.S.A.
Phone:
925-730-8000
Fax:
925-225-0479
|
Roche Molecular Diagnostics (operating in the U.S. as Roche Molecular Systems) develops and produces molecular-based diagnostic tests and automated testing platforms using the Nobel-prize winning polymerase chain reaction (PCR) technology. The Company has six unique areas of interest in the healthcare arena: Virology, Blood Screening, Microbiology, Genomics, Women's Health and Oncology. With its uniquely broad nucleic acid technology (NAT) portfolio, RMD supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories worldwide.
In clinical molecular diagnostics, Roche has made PCR the leading DNA based technology and has provided the basis for unprecedented advances in the diagnosis and monitoring of life-threatening diseases such as AIDS and hepatitis. PCR's extreme sensitivity makes it possible to diagnose infectious agents earlier and to monitor disease progression and response to therapy. Additionally, blood banks rely on Roche PCR tests to help ensure the safety of donated blood and blood products . Roche Molecular Diagnostics continues to build on this commitment by working on new applications in the use of PCR in the areas of infectious diseases, hereditary disorders, genetic markers and drug susceptibility. The ability to identify predisposition for diseases, with earlier disease screening and tailored patient therapy, will result in earlier treatment and improved patient care.
Centers of Excellence for Roche Molecular Systems
Alameda (US): Research of new markers in infectious diseases, microbiology, genetics, disease predisposition, and drug susceptibility
Belleville (US): Manufacturing of AMPLICOR kits and related products
Pleasanton (US): Product development, regulatory, clinical, business development and strategic marketing support of the AMPLICOR products
Rotkreuz (CH): Development and production of systems (instruments) and lab network solutions (software)
Penzberg (CH): Research, development and production for both Pharmaceuticals and Diagnostics, while practicing the art of combining machines, reagents and software intelligently.
Email:
Ownership:
Web Site:
Roche Molecular Systems, Inc.
Employees:
Approximately 1115
Symbol: RHHBF.PK
|
|
|
Company News |
Myriad Genetics, Inc. (MYGN) Elects Former Roche Molecular Systems, Inc. (RHHBF.PK) CEO Heiner Dreismann to Its Board of Directors
6/11/2010 10:33:28 AM
More...
|
Preliminary Data from Roche Molecular Systems, Inc. (RHHBF.PK) ATHENA Cervical Cancer Trial Support Value of Human Papillomavirus Genotyping
2/18/2010 11:19:57 AM
More...
|
Roche Molecular Systems, Inc. (RHHBF.PK) Collaborates with Merck Sharp & Dohme (MRK) on Developmental Test for Cancer-Related Gene Mutation Investigational AmpliChip p53 Test Designed to Screen for Genetic Mutation Tied to Therapeutic Resistance in Cancer Patients
2/17/2010 10:21:57 AM
More...
|
Roche Molecular Systems, Inc. (RHHBF.PK) Research Team Uses 454 Life Sciences Sequencing System for High-Resolution HLA Genotyping
10/27/2009 9:01:04 AM
More...
|
DeviceSpace Launches the 2009 U.S. Device™ Hotbed Campaign
6/26/2009 4:35:56 PM
More...
|
Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems, Inc. (RHHBF.PK) and Diagnostics Veteran, Joins Shrink Nanotechnologies Board of Directors
6/25/2009 8:49:34 AM
More...
|
Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc. (RHHBF.PK)
12/16/2008 6:51:45 AM
More...
|
Arcxis Biotechnologies and Roche Molecular Systems, Inc. (RHHBF.PK) Initiate Research Collaboration to Apply New Technology for Diagnostic Sample Preparation
9/23/2008 10:01:20 AM
More...
|
Asuragen, Inc. Licenses Roche Molecular Systems, Inc. (RHHBF.PK)'s Real-time Quantitative PCR Technology for Clinical Gene Expression Profiling
10/8/2007 11:20:57 AM
More...
|
Iconix Biosciences Adds Former President And CEO Of Roche Molecular Systems, Inc. (RHHBF.PK) To Its Board Of Directors
10/18/2006 12:09:49 PM
More...
|
|
|
|